(Q38248687)

1 September 2017

1 reference

title

Animal models of Huntington's disease for translation to the clinic: best practices (English)

1 reference

1 September 2017

0 references

1 reference

Liliana Menalled

1

1 reference

PubMed ID

25216369

1 September 2017

Daniela Brunner

series ordinal

2

1 reference

PubMed ID

25216369

1 September 2017

language of work or name

English

0 references

publication date

1 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

29

1 reference

1 September 2017

11

1 reference

1 September 2017

1375-1390

1 reference

Of mice and not men: differences between mouse and human immunology

1 September 2017

1 reference

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

21 January 2018

1 reference

Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

21 January 2018

1 reference

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

21 January 2018

1 reference

Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice

21 January 2018

1 reference

A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse

21 January 2018

1 reference

Scientific rigor and the art of motorcycle maintenance

21 January 2018

1 reference

Knock-in mouse models of Huntington's disease

21 January 2018

1 reference

Mouse models of polyglutamine diseases: review and data table. Part I

21 January 2018

1 reference

Rodent genetic models of Huntington disease

21 January 2018

1 reference

Choosing an animal model for the study of Huntington's disease

21 January 2018

1 reference

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

21 January 2018

1 reference

Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

21 January 2018

1 reference

Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

21 January 2018

1 reference

Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding

21 January 2018

1 reference

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease

21 January 2018

1 reference

Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice

21 January 2018

1 reference

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice

21 January 2018

1 reference

Neurological abnormalities in a knock-in mouse model of Huntington's disease

21 January 2018

1 reference

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats

21 January 2018

1 reference

Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse

21 January 2018

1 reference

A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice

21 January 2018

1 reference

Early autophagic response in a novel knock-in model of Huntington disease

21 January 2018

1 reference

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.

21 January 2018

1 reference

HD mouse models reveal clear deficits in learning to perform a simple instrumental response

21 January 2018

1 reference

Drug development: Raise standards for preclinical cancer research

21 January 2018

1 reference

Why most published research findings are false

21 January 2018

1 reference

Believe it or not: how much can we rely on published data on potential drug targets?

21 January 2018

1 reference

Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review

21 January 2018

1 reference

Dissemination and publication of research findings: an updated review of related biases

21 January 2018

1 reference

Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration

21 January 2018

1 reference

Fighting publication bias: introducing the Negative Results section

21 January 2018

1 reference

Uncovering negative results: Introducing an open access journal "Journal of Pharmaceutical Negative Results".

21 January 2018

1 reference

Rise and fall of minocycline in neuroprotection: need to promote publication of negative results

21 January 2018

1 reference

Why Most Discovered True Associations Are Inflated

21 January 2018

1 reference

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

21 January 2018

1 reference

Bayesian t tests for accepting and rejecting the null hypothesis.

21 January 2018

1 reference

Power failure: why small sample size undermines the reliability of neuroscience

21 January 2018

1 reference

Design, power, and interpretation of studies in the standard murine model of ALS

21 January 2018

1 reference

Guidelines for preclinical animal research in ALS/MND: A consensus meeting

21 January 2018

1 reference

Preclinical research in Rett syndrome: setting the foundation for translational success.

21 January 2018

1 reference

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies

21 January 2018

1 reference

Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease

21 January 2018

1 reference

A call for transparent reporting to optimize the predictive value of preclinical research

21 January 2018

1 reference

Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice

21 January 2018

1 reference

Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models

21 January 2018

1 reference

Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain

21 January 2018

1 reference

Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

Neural consequences of environmental enrichment

21 January 2018

1 reference

Delaying the onset of Huntington's in mice

21 January 2018

1 reference

Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease

21 January 2018

1 reference

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice

21 January 2018

1 reference

Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene

21 January 2018

1 reference

Unstressing intemperate models: how cold stress undermines mouse modeling

21 January 2018

1 reference

Drug discovery in academia

21 January 2018

1 reference

SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition

21 January 2018

1 reference

Cognitive impairment in Huntington disease: diagnosis and treatment

21 January 2018

1 reference

Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine.

21 January 2018

1 reference

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse

21 January 2018

1 reference

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

21 January 2018

1 reference

Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease

21 January 2018

1 reference

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

21 January 2018

1 reference

Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease

21 January 2018

1 reference

Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease.

21 January 2018

1 reference

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin

21 January 2018

1 reference

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

21 January 2018

1 reference

Tetrabenazine is neuroprotective in Huntington's disease mice

21 January 2018

1 reference

Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice

21 January 2018

1 reference

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

21 January 2018

1 reference

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase

21 January 2018

1 reference

Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease

21 January 2018

1 reference

A futility study of minocycline in Huntington's disease

21 January 2018

1 reference

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease.

21 January 2018

1 reference

A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

21 January 2018

1 reference

Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial

21 January 2018

1 reference

A controlled trial of remacemide hydrochloride in Huntington's disease

21 January 2018

1 reference

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study

21 January 2018

1 reference

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

21 January 2018

1 reference

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

21 January 2018

1 reference

Negative results and impact factor: a lesson from neonatology

21 January 2018

1 reference

COCI

https://opencitations.net/index/coci/api/v1/citations/10.1001/ARCHPEDI.159.11.1036

13 November 2021

Identifiers

DOI

10.1002/MDS.26006

1 reference

1 September 2017

1 reference

PubMed ID

25216369